For all plasma samples (n = 309) from patients who had RAS/BRAF-mutant tumors, the cfDNA tumor burden was determined using the mutant allele frequency (MAF) of the tumor-informed RAS/BRAF mutation as measured by ddPCR (Supplementary Data 2). This evidence concerns the gene BRAF and neoplasm.